Navigation Links
1 dose of H1N1 vaccine may provide sufficient protection for infants and children
Date:12/21/2009

CHICAGO -- One dose of vaccine may be effective to protect infants and children and reduce transmission of the H1N1 virus, according to a study in JAMA, published online today because of its public health implications. The study will appear in the January 6 print edition of the journal.

Initial reports of 2009 influenza A(H1N1) infection in many countries have largely involved children, especially those attending school. Reports have also indicated high hospitalization rates of children younger than 5 years of age in the current pandemic, according to background information provided by the authors. "The Advisory Committee on Immunization Practices also currently recommends that infants and children aged 9 years or younger receive two doses of H1N1 influenza vaccine at least 21 days apart, based on existing experience with seasonal trivalent influenza vaccines in this age group."

Terry Nolan, M.B.B.S., Ph.D., from the University of Melbourne, Australia and colleagues assessed the effectiveness and safety of two doses of a 2009 influenza A(H1N1) vaccine in 370 healthy infants and children ages six-months to less than 9 years living in Australia. The children were randomized into groups that received a two-injection regimen 21 days apart in doses of either 15-micrograms or 30-micrograms of the vaccine.

"Following the first dose of vaccine, antibody titers of 1:40 or greater were observed in 161 of 174 infants and children in the 15-microgram group (92.5 percent) and in 168 of 172 infants and children in the 30 microgram group (97.7 percent)," the authors report. "All participants demonstrated antibody titers of 1:40 or greater after the second vaccine dose," [which means that every child achieved an antibody level considered high enough to protect against the H1N1 virus]. The researchers note that the majority of adverse reactions to the vaccine were mild to moderate in severity. The immune responses to the vaccine were strong regardless of age, baseline antibody status, or whether the child had received a seasonal influenza vaccination prior to this study.

"Our findings suggest that a single dose 15-microgram dose vaccine regimen may be effective and well tolerated in children, and may have positive implications for disease protection and reduced transmission of pandemic H1N1 in the wider population," the authors conclude.

(JAMA. 2010; 303[1]:[doi:10.1001/JAMA.2009/1911]. Available pre-embargo to the media at www.jamamedia.org)

Editor's Note: This study was sponsored by CSL Limited with funding from the Australian government's Department of Health and Ageing. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: 2009 Influenza A(H1N1) Vaccines for Children

"Even though influenza activity has decreased in recent weeks in some states, there remains the possibility of continued activity through the traditional winter influenza season and the prospect of normal winter circulation of seasonal influenza viruses," and the authors of the editorial note that this pandemic has highlighted the fact the children have no measurable immunity against the H1N1 virus.

Anthony E. Fiore, M.D., M.P.H., from the National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, and Kathleen M. Neuzil, M.D., M.P.H., of PATH, Seattle, write that children have been a primary source of illness in community outbreaks of pandemic influenza with more severe complications, hospitalizations and deaths from this virus than what is usually seen for seasonal influenza.

The editorial authors urge caution at interpretation of the results of the study. "The hemagglutinin antigen content administered to six-month-old infants and children younger than 3 years in this study was 15-micrograms, the equivalent of two doses of the 7.5-microgram vaccine currently licensed in the United States for this age group."

"The immunogenicity data presented by Nolan et al suggest that at least some children will be protected after a single 15-microgram dose of the H1N1 vaccine used in this study, but the findings cannot be generalized with confidence to all children, epidemiological circumstances in every country, or different vaccine formulations."

In conclusion, the authors write: " it remains prudent to continue to follow current recommendations for administering two doses to infants and young children while awaiting definitive vaccine effectiveness data."


'/>"/>

Contact: Terry Nolan, M.B.B.S., Ph.D.
t.nolan@unimelb.edu.au
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Single Shot of H1N1 Vaccine May Be Enough for Kids
2. Scientists Spot Source of Hurdle to AIDS Vaccine
3. Large Recall of Childrens Swine Flu Vaccine
4. Research reveals further progress toward AIDS vaccine
5. Better Vaccine Planning Needed, Committee Finds
6. IOM report on national vaccine plan
7. Centegra Expands H1N1 Vaccines to General Public
8. American adults receiving flu vaccine at about the same rate as in 2008, study finds
9. Nearly 3 Million Doses of H1N1 Vaccine Allocated to Pennsylvania since Start of Vaccination Effort
10. Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children
11. Ninety Percent of All Vaccine Preventable Deaths Occur in Those 65 and Older According to Highlighted Studies in the December Patient Safety Advisory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... ... Robert E. Burke, MD, PhD, had a successful career as a pediatrician and ... have led him down a much different path. , In his book, “Beyond the ... Dr. Burke shares a personal account of the tribulations he encountered on his path ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear warfare has long plagued ... involved in the underground testing of nuclear weapons. Years later, when her co-workers began ... the Cold War Nuclear Testing,” Clayton exposes the critical decisions made by agencies involved ...
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar ... analysis as a tool to characterize particle size distributions in the field of ... results and novel scientific findings. It describes methods of optimized and standardized sample ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based retail electric company ... Power's RCE (Residential Customer Equivalent) count exceeds 150,000. , Discount Power ... customers and 2,250 RCEs at the time of acquisition. In the three years ...
(Date:2/27/2017)... San Francisco, CA (PRWEB) , ... February 27, ... ... transplant clinic serving San Francisco and environs, is proud to announce an upgrade ... research information on the upgraded Yelp page on topics as diverse as Platelet ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017   Vitasome ® ... of nutritional supplements using its groundbreaking new liposome technology. ... percent of potency through digestion per Physician,s Desk ... solve the problem of nutritional waste and are scientifically ... during digestive processes Improve bioavailability with ...
(Date:2/27/2017)... A recent research report published by Grand ... is expected to reach a value of $55.8 billion by 2025. ... 28 states have legalized marijuana for medical uses. In 2016, states ... , North Dakota , Ohio ... the drug in medical applications such as chemotherapies and pain management. ...
(Date:2/27/2017)... The Hague, The Netherlands , Feb 27, 2017 /PRNewswire/ ... Sectra Tiger/R is approved by NATO for use at ... requirements on security imposed within the NATO organization for the ... ... aimed at providing government authorities with an eavesdrop-secure smartphone solution. ...
Breaking Medicine Technology: